Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Edmund Ingham Investing Group Leader Follow Summary Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029. I assign a Hold rating to AURA stock due to long timelines, pivotal trial risk, and lack of near-term catalysts, but recognize significant upside if Bel-sar succeeds. Looking for more investing ideas like this one? Get them exclusively at Haggerston BioHealth. Learn More » Nicolae Popescu/iStock via Getty Images Investment Overview This is the first time I have covered Aura Biosciences, Inc. ( AURA ) for Seeking Alpha—the Boston, Massachusetts-based pharma completed its Initial Public Offering (“IPO”) in October 2021, raising ~$75.6m via the issuance of ~5.4m shares This article was written by Edmund Ingham 15.11K Followers Follow Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, discounted cash flow analysis and market by market analysis. Learn more. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.